JPH0465049B2 - - Google Patents
Info
- Publication number
- JPH0465049B2 JPH0465049B2 JP56502536A JP50253681A JPH0465049B2 JP H0465049 B2 JPH0465049 B2 JP H0465049B2 JP 56502536 A JP56502536 A JP 56502536A JP 50253681 A JP50253681 A JP 50253681A JP H0465049 B2 JPH0465049 B2 JP H0465049B2
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine
- brain
- tryptophan
- levels
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 43
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 43
- 210000004556 brain Anatomy 0.000 description 24
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 24
- 150000003943 catecholamines Chemical class 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 19
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 18
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 18
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 210000000225 synapse Anatomy 0.000 description 15
- 229940076279 serotonin Drugs 0.000 description 12
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 9
- 239000000902 placebo Substances 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
- 229960002748 norepinephrine Drugs 0.000 description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 5
- 229960005139 epinephrine Drugs 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229940001470 psychoactive drug Drugs 0.000 description 3
- 239000004089 psychotropic agent Substances 0.000 description 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 244000089486 Phragmites australis subsp australis Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020931 dietary conditions Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- -1 leucine Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1981/000963 WO1982000250A1 (en) | 1980-07-15 | 1981-07-15 | Process for improving vigor and mood in normal human patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58501117A JPS58501117A (ja) | 1983-07-14 |
| JPH0465049B2 true JPH0465049B2 (cs) | 1992-10-16 |
Family
ID=22161322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50253681A Granted JPS58501117A (ja) | 1981-07-15 | 1981-07-15 | 正常なひと患者における精神賦活剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58501117A (cs) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100305095A1 (en) * | 2006-08-18 | 2010-12-02 | Kim Zachary Travis | Use of HPPD Inhibitors in the Treatment of Depression and/or Withdrawal Symptoms Associated with Addictive Drugs |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4862917A (cs) * | 1971-12-09 | 1973-09-01 | ||
| JPS5228946A (en) * | 1975-07-28 | 1977-03-04 | Ajinomoto Co Inc | Amino acid infusion |
| JPS5627493A (en) * | 1979-08-14 | 1981-03-17 | Nippon Electric Co | Method and device for identifying bill |
-
1981
- 1981-07-15 JP JP50253681A patent/JPS58501117A/ja active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4862917A (cs) * | 1971-12-09 | 1973-09-01 | ||
| JPS5228946A (en) * | 1975-07-28 | 1977-03-04 | Ajinomoto Co Inc | Amino acid infusion |
| JPS5627493A (en) * | 1979-08-14 | 1981-03-17 | Nippon Electric Co | Method and device for identifying bill |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58501117A (ja) | 1983-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Birkmayer et al. | Implications of combined treatment with'Madopar'and L-deprenil in Parkinson's disease: a long-term study | |
| Kernbaum et al. | Administration of levodopa for relief of herpes zoster pain | |
| RU2140266C1 (ru) | Фармацевтическая композиция с регулируемым выделением на основе одной или нескольких фармацевтически приемлемых солей гамма-гидроксимасляной кислоты и способ ее получения | |
| DK174017B1 (da) | Anvendelse af gamma-hydroxysmørsyresalte til fremstilling af farmaceutiske præparater til behandling af alkoholisme | |
| US4962121A (en) | Method and composition for treating neurological diseases such as migraine | |
| Lindén | Vitamin D and myocardial infarction | |
| US10028991B2 (en) | Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication | |
| Amer et al. | 5-Hydroxy-L-tryptophan suppresses food intake in food-deprived and stressed rats | |
| Glasauer | Restless legs syndrome | |
| US20090018151A1 (en) | Topical Treatment of Peripheral diabetic complications | |
| US4435424A (en) | Process for improving vigor and mood in normal human patients | |
| KR20090033871A (ko) | 비페프루녹스 및 ｌ-ｄｏｐａ를 포함하는 병용 제제 | |
| MX2007006091A (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante. | |
| JP2001510800A (ja) | 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用 | |
| Hollister | Clinical use of psychotherapeutic drugs II: antidepressant and antianxiety drugs and special problems in the use of psychotherapeutic drugs | |
| JPH0465049B2 (cs) | ||
| US4327112A (en) | Process for increasing blood pressure | |
| RU2096034C1 (ru) | Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием | |
| CA1320133C (en) | Analgesic drug comprising l-tryptophan | |
| EP0056401A1 (en) | Process for improving vigor and mood in normal human patients | |
| US4745130A (en) | Composition for increasing blood pressure | |
| Ekblom et al. | L-Tryptophan supplementation does not affect postoperative pain intensity or consumption of analgesics | |
| Manyam | Practical guidelines for management of Parkinson disease | |
| Pelissier-Alicot et al. | Time-of-day dependent pharmacodynamic and pharmacokinetic profiles of caffeine in rats | |
| JPH01197485A (ja) | 恐慌状態の予防または断絶のための薬剤 |